Valganciclovir is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).

Valganciclovir is also indicated for the prevention of CMV disease in CMV-negative patients who have received a solid organ transplant from a CMV-positive donor.
Active ingredient Pharmaceutical form Package Therapeutic target
  • Valganciclovir
  • F.c. Tablets
  • 450mg
  • Infections-Antiviral

Other products in "International"